8-K: BioMarin to Acquire Amicus for $4.8B, Boosting Rare Disease Portfolio

BioMarin Pharmaceutical Inc. announced a definitive agreement to acquire Amicus Therapeutics for $4.8 billion in cash, expanding its rare disease portfolio with two marketed therapies and a late-stage candidate.

Summary

• BioMarin Pharmaceutical Inc. will acquire Amicus Therapeutics, Inc. for $14.50 per share in an all-cash transaction, totaling approximately $4.8 billion in equity value.
• The acquisition will add two marketed rare disease treatments to BioMarin's portfolio: Galafold (migalastat) for Fabry disease and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) for Pompe disease.
• These products generated combined net product revenues of $599 million over the past four quarters.
• Amicus also holds U.S. rights to DMX-200, an investigational small molecule for focal segmental glomerulosclerosis (FSGS) in Phase 3 development.
• The transaction is expected to close in the second quarter of 2026, subject to regulatory clearances and Amicus stockholder approval.
• BioMarin plans to finance the acquisition through cash on hand and approximately $3.7 billion in non-convertible debt financing, targeting gross leverage below 2.5x within two years post-close.
• Patent litigation for Galafold has been resolved, securing U.S. exclusivity through January 2037, with generic licenses granted to Aurobindo and Lupin starting January 30, 2037.

Sentiment

Score: 8

Explanation: The filing announces a significant strategic acquisition with clear financial benefits for the acquirer (revenue growth, EPS accretion, portfolio diversification) and a substantial premium for the target's shareholders. The resolution of patent litigation for a key product further de-risks the deal. While debt financing is involved, a deleveraging commitment is stated. The overall tone is highly positive regarding the strategic fit and anticipated value creation.

Positives

• Expands BioMarin's rare disease product portfolio with two marketed, high-growth products: Galafold and Pombiliti + Opfolda.
• Accelerates BioMarin's revenue growth immediately after close and is expected to increase long-term CAGR through 2030 and beyond.
• Expected to be accretive to Non-GAAP Diluted EPS in the first 12 months post-close and substantially accretive beginning in 2027.
• Strengthens and diversifies BioMarin's commercial portfolio, providing expansion opportunities across its global footprint.
• Resolution of Galafold patent litigation secures U.S. exclusivity through January 2037.
• Adds a potential first-in-class investigational small molecule, DMX-200, in Phase 3 development for FSGS.
• Demonstrates execution of BioMarin's capital allocation strategy to leverage financial strength for pipeline diversification and innovative therapies.

Negatives

• The acquisition involves significant debt financing of approximately $3.7 billion, which will increase BioMarin's leverage, although a commitment to deleveraging to <2.5x within two years is stated.
• Amicus will pay a termination fee of $175,000,000 to BioMarin under certain circumstances, indicating potential financial risk for Amicus if the deal falls through due to its actions.
• Generic versions of Galafold will be allowed in the U.S. starting January 30, 2037, which will eventually impact revenue from that product.

Risks

• Consummating the proposed acquisition and financing in the anticipated timeframe, if at all.
• Whether Amicus stockholders will approve the acquisition.
• The possibility that competing offers or acquisition proposals will be made.
• The possibility that various closing conditions for the transaction may not be satisfied or waived, including governmental entities prohibiting, delaying, or refusing approval (or granting approval with adverse conditions).
• Difficulty in predicting the timing or outcome of regulatory approvals or actions.
• Unknown or inestimable liabilities.
• The parties' ability to realize the anticipated benefits of the proposed acquisition, including successful integration and realization of expected benefits within the expected time period.
• Obtaining and maintaining adequate coverage and reimbursement for BioMarin's or Amicus's products.
• The costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in clinical trials for DMX-200.
• Global economic, financial, and healthcare system disruptions and their potential negative impacts.
• Sufficiency of BioMarin's or Amicus's cash flows and capital resources, and BioMarin's ability to fund the acquisition.
• The effects of the transaction on relationships with key third parties, including employees, customers, suppliers, and business partners, and the risk of adverse effects on employee retention.
• Transaction costs.
• Risks that the proposed acquisition disrupts current plans and operations or diverts management's attention.
• Changes in Amicus's business during the period between announcement and closing.
• Any legal proceedings and/or regulatory actions related to the proposed acquisition.

Future Outlook

BioMarin expects the acquisition to accelerate its revenue growth and strengthen its financial outlook immediately upon close, increasing its long-term compound annual growth rate (CAGR) through 2030 and beyond. The transaction is projected to be accretive to Non-GAAP Diluted EPS in the first 12 months post-close and substantially accretive starting in 2027. BioMarin is committed to deleveraging, targeting gross leverage below 2.5x within two years after closing. The acquisition is also expected to expand access to Galafold and Pombiliti + Opfolda to patients in new markets and advance the development of DMX-200.

Management Comments

• "Amicus, like BioMarin, is a company that has been profoundly dedicated to transforming care for patients with rare diseases since its founding, developing and bringing to market important therapies for individuals living with Fabry disease and Pompe disease. BioMarin’s scale of operations, including our global commercial footprint and industry-leading, in-house manufacturing capabilities make the combination of these companies an exceptional strategic fit." Alexander Hardy, President and CEO of BioMarin.
• "Immediately upon close, this transaction is expected to accelerate BioMarin’s revenue growth and strengthen our financial outlook, delivering significant value to patients, employees and stockholders." Alexander Hardy, President and CEO of BioMarin.
• "I am enormously proud of our Amicus team. Together with our partners in the rare disease community, we created a truly patient-centric biotech and successfully developed two transformative medicines for people living with rare diseases, which impacted the lives of more than 3,400 patients around the world." Bradley L. Campbell, President and CEO of Amicus.
• "With BioMarin’s unwavering commitment to patients, along with greater resources and scale, Amicus medicines will reach even more patients around the world, faster. We are confident that this agreement is in the best interests of our shareholders by providing compelling, certain and premium value, and will accelerate progress for the rare disease community." Bradley L. Campbell, President and CEO of Amicus.

Industry Context

This acquisition reinforces the trend of consolidation within the rare disease biotechnology sector, where larger players like BioMarin seek to expand and diversify their specialized portfolios. The focus on lysosomal storage disorders and a late-stage kidney disease candidate aligns with the industry's drive for high-value, unmet medical needs. The resolution of patent litigation for Galafold also highlights the ongoing importance of intellectual property protection and strategic settlements in the pharmaceutical industry.

Comparison to Industry Standards

• The acquisition premium of 33% to Amicus's last close, 46% to the 30-day volume-weighted average stock price, and 58% to the 60-day volume-weighted average stock price is a significant premium, generally considered attractive for target shareholders in the biotechnology M&A landscape.
• The target of gross leverage <2.5x within two years post-close for BioMarin indicates a commitment to financial discipline, which is a common benchmark for maintaining a healthy balance sheet post-acquisition in the pharmaceutical industry.
• The addition of two marketed therapies (Galafold and Pombiliti + Opfolda) with combined net product revenues of $599 million over the past four quarters, along with a Phase 3 candidate (DMX-200), positions BioMarin to enhance its market presence in rare diseases, a strategy often employed by leading biotech firms to sustain growth.

Corporate Governance

Legal Proceedings

• Patent litigation relating to Galafold with Aurobindo Pharma and Lupin Ltd. has been resolved.
• License Agreements grant Aurobindo and Lupin licenses to market generic versions of Galafold in the U.S. beginning January 30, 2037.
• All ongoing Hatch-Waxman litigation between Amicus and Aurobindo and Lupin regarding Galafold patents in the U.S. District Court for the District of Delaware will be terminated.

Stakeholder Impact

• Shareholders (Amicus): Will receive $14.50 per share in cash, representing a significant premium, providing compelling and certain value.
• Shareholders (BioMarin): Expected to benefit from accelerated revenue growth, strengthened financial outlook, increased long-term CAGR, and accretive Non-GAAP Diluted EPS.
• Employees (Amicus): BioMarin commits to providing comparable base salary/wage rate, target cash incentive compensation, and other compensation/benefits for a period of one year post-merger. Service credit for eligibility/vesting in BioMarin's plans will be recognized. However, there's a risk of adverse effects on employee retention and potential disruptions to current plans and operations.
• Patients: Expected to benefit from expanded access to Galafold and Pombiliti + Opfolda in new markets due to BioMarin's global footprint and resources.
• Creditors: BioMarin intends to finance the transaction with approximately $3.7 billion in debt, with a commitment to deleveraging, impacting BioMarin's debt profile.
• Suppliers/Business Partners: Potential for effects on relationships, including the risk that the proposed acquisition adversely affects these relationships.

Next Steps

• Amicus to prepare and file a preliminary proxy statement within 20 business days after the Agreement Date.
• Amicus to establish a record date, duly call, convene, and hold a meeting of its stockholders for the purpose of voting upon the adoption of the Merger Agreement.
• BioMarin and Amicus to make appropriate filings under the HSR Act and other antitrust laws within 20 business days after the Agreement Date.
• BioMarin to obtain approximately $3.7 billion in non-convertible debt financing.
• The merger is expected to close in the second quarter of 2026.
• BioMarin targets gross leverage <2.5x within two years after close.
• Amicus to deliver a customary payoff letter for the Senior Secured Term Loan Agreement at least three business days prior to closing.
• The Company to cooperate with Parent to delist Shares from Nasdaq and deregister under the Exchange Act after the Effective Time.

Key Dates

Recommendation

The acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc. is a highly strategic move that significantly enhances BioMarin's rare disease portfolio with two established, high-growth products (Galafold and Pombiliti + Opfolda) and a promising late-stage candidate (DMX-200). The deal is expected to be immediately accretive to BioMarin's revenue growth and Non-GAAP Diluted EPS, with substantial accretion projected from 2027. The resolution of Galafold patent litigation provides long-term U.S. exclusivity, de-risking a key asset. While the acquisition involves debt, BioMarin's commitment to deleveraging within two years demonstrates financial prudence. For Amicus shareholders, the all-cash offer represents a substantial premium, offering immediate and certain value. This transaction positions BioMarin for sustained long-term growth and strengthens its leadership in the rare disease market, making it a compelling investment opportunity.

Keywords

BioMarin, Amicus Therapeutics, Acquisition, Rare Disease, Fabry disease, Pompe disease, Galafold, Pombiliti, Opfolda, DMX-200, FSGS, Biotechnology, Merger, Pharmaceutical, SEC Filing, M&A, Drug Development, Clinical Trials, Patent Litigation